The Albany Gazette - Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NYSE - LSE

BTI	3.29%	62.97	$
BCC	4.07%	77.98	$
RIO	3.48%	84.56	$
CMSC	2.5%	20.36	$
BCE	2.7%	21.11	$
GSK	4.79%	51.15	$
NGG	2.8%	85.22	$
AZN	2.71%	189.01	$
BP	-4.34%	45.61	$
CMSD	2.02%	20.27	$
RYCEF	-0.06%	16.91	$
RBGPF	7.49%	76.2	$
JRI	2.41%	11.64	$
RELX	4.09%	41.08	$
VOD	4.05%	16.28	$

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ECONOMY 14.03.2025

Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / March 14, 2025 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) and Calidi Biotherapeutics, Inc. (NYSE American:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

Text size:

Access the interviews in their entirety at:

In an exclusive interview, Nexalin CEO Mark White appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to share insight into the Company's growing clinical data supporting its non-invasive, frequency-based deep brain stimulation device, as well as progress on its new Gen-3 HALO™ Clarity & Virtual Clinic model. Nexalin's solutions have shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries-conditions that affect millions but have limited effective treatments-positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach $537 billion by 2030.

In an exclusive interview, Andrew Jackson, CFO of Calidi Biotherapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's innovative approach to transforming cancer treatment through its proprietary oncolytic virotherapy (OV) platforms. Jackson highlights Calidi's novel stem cell-based technology, designed to protect, amplify, and potentiate oncolytic viruses, enabling a more effective and targeted attack on cancer cells. He provides insights into Calidi's robust clinical pipeline, including CLD-101, currently in a Phase 1/1b trial with an upcoming Phase 1b/2 study, and CLD-201, targeting Phase 1 initiation in 2025. Additionally, Jackson outlines the company's significant market opportunity, with an addressable U.S. market estimated at $13 billion to $15 billion. With early clinical signals demonstrating efficacy and safety, and a leadership team experienced in building successful biotech companies, Calidi is well-positioned to advance next-generation cancer therapies and drive long-term value for investors.

NXL and CLDI are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.

About Nexalin Technology, Inc.

Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman. Additional information about the Company is available at: https://nexalin.com/.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSE American:CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi's novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi's clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi's preclinical off-the-shelf enveloped virotherapies, are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.

About RedChip Companies

RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.

To learn more about RedChip's products and services, please visit:

https://www.redchip.com/corporate/investor_relations

"Discovering Tomorrow's Blue Chips Today"™

Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340

Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest

Contact:

Dave Gentry
RedChip Companies Inc.
1-407-644-4256
[email protected]

SOURCE: RedChip Companies Inc.

View the original press release on ACCESS Newswire

(O.Garcia--TAG)

Featured

UK Taxpayers Warned to Verify Codes Before April 2027 Savings Rate Hike

Harvey Dhillon, founder of Zmartly, advises UK residents to verify their HM Revenue and Customs tax codes immediately. This precaution is critical as the government proposes raising savings interest tax rates by two percentage points starting in April 2027, potentially increasing annual liabilities for millions of taxpayers.

Mutual fund returns show shifting leaders across market-cap categories

Equity mutual funds are classified into different categories based on their investments across market capitalisations, primarily large-cap, mid-cap, and small-cap funds. Large-cap funds invest in well-established companies that tend to be relatively less volatile, while mid-cap funds focus on medium-sized companies.

BHEL Secures ₹28,000 Crore in Adani Power Contracts

State-owned Bharat Heavy Electricals Limited (BHEL) announced on Wednesday that it has secured four major contracts from Adani Power Limited. The orders, valued at up to ₹28,000 crore, involve the supply of critical power generation equipment and associated services for new thermal plants across India.

BHEL wins Adani Power projects valued at up to ₹28,000 crore

New Delhi, Nov 4 (PTI) State-owned BHEL on Wednesday said the company has received four projects, worth ranging between Rs 20,000 crore and Rs 28,000 crore, from Adani Power. The fresh orders involve supply of equipment (boiler, turbine and generator along with auxiliaries) and agreed services for the said projects, BHEL said in an exchange filing.